Evaxion A/S (NASDAQ:EVAX – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a report on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Evaxion A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.25.
Read Our Latest Report on EVAX
Evaxion A/S Price Performance
NASDAQ:EVAX opened at $2.74 on Friday. The firm has a market cap of $24.72 million, a P/E ratio of -2.26 and a beta of 0.60. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.06 and a current ratio of 5.06. Evaxion A/S has a fifty-two week low of $2.65 and a fifty-two week high of $6.92. The firm has a 50-day simple moving average of $3.13 and a two-hundred day simple moving average of $3.43.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Evaxion A/S during the first quarter valued at $112,000. Renaissance Technologies LLC purchased a new stake in shares of Evaxion A/S during the first quarter valued at $146,000. Finally, Rathbones Group PLC bought a new stake in Evaxion A/S in the 1st quarter worth about $170,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.
Evaxion A/S Company Profile
Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.
Further Reading
- Five stocks we like better than Evaxion A/S
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.
